Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 63

Results For "FDA"

2507 News Found

FDA approves Roche’s Vabysmo PFS for three leading causes of vision loss
News | July 06, 2024

FDA approves Roche’s Vabysmo PFS for three leading causes of vision loss

Vabysmo PFS is the first and only syringe prefilled with an FDA-approved bispecific antibody to treat retinal conditions that can cause blindness


Alembic Pharmaceuticals announces USFDA final approval for Doxycycline Capsules, 40 mg
Drug Approval | June 29, 2024

Alembic Pharmaceuticals announces USFDA final approval for Doxycycline Capsules, 40 mg

Doxycycline capsules are indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients


Jubilant Ingrevia receives EIR from USFDA for Unit-1 at Bharuch
Drug Approval | June 28, 2024

Jubilant Ingrevia receives EIR from USFDA for Unit-1 at Bharuch

This existing GMP compliant facility, located at Bharuch (Unit-1) with ongoing expansion part of the company's strategic capex initiative


Eugia SEZ’s injectable facility gets EIR from USFDA
Drug Approval | June 28, 2024

Eugia SEZ’s injectable facility gets EIR from USFDA

The Unit has now received Establishment Inspection Report classifying the facility as Voluntary Action Indicated


Shilpa Medicare Bio Analytical unit gets
Drug Approval | June 27, 2024

Shilpa Medicare Bio Analytical unit gets "No Action Indicated" classification from USFDA

This Unit of Shilpa Medicare is engaged in testing biological samples of clinical studies


Lupin receives EIR from US FDA for its Somerset manufacturing facility
Drug Approval | June 25, 2024

Lupin receives EIR from US FDA for its Somerset manufacturing facility

The facility was inspected from May 7 to May 17, 2024


Cipla gets 6 observations from USFDA for Goa facility
Drug Approval | June 24, 2024

Cipla gets 6 observations from USFDA for Goa facility

The company will work closely with the USFDA and is committed to address these comprehensively within stipulated time


Bristol Myers Squibb receives USFDA accelerated approval of Krazati in combination with Cetuximab for CRC
Drug Approval | June 22, 2024

Bristol Myers Squibb receives USFDA accelerated approval of Krazati in combination with Cetuximab for CRC

Second FDA approval for KRAZATI - reinforcing its potential across tumor types


Roche receives FDA clearance on its digital pathology solution for diagnostic use
News | June 20, 2024

Roche receives FDA clearance on its digital pathology solution for diagnostic use

This clearance is a foundational step in Roche's commitment to enable routine clinical diagnosis with its digital pathology solutions